Session Chair: Elín Soffía Ólafsdóttir
13:35-13:50: Drug development of the phenazine 5,10-dioxide natural products iodinin and myxin into antileukemic candidates
13:50-14:05: Design of Experiments for Optimization of UPLC-MS/MS Assay – get it right from the beginning
14:05-14:20: UPLC-MS/MS-Based Plasma Assay for Therapeutic Drug Monitoring in Patients with APRT Deficiency
14:20-14:35: Designing 3D printed patch for hand osteoarthritis
Abstracts in session A-Z
Margrét Þorsteinsdóttir. Method development can become more efficient by utilizing design of experiments (DoE) for optimization of UPLC-MS/MS assay for simultaneous quantification of biomarkers in biological matrices with only a fraction of experiments that would be required by changing one-factor-at-time (OFAT) approach.
Bergþóra Sigríður Snorradóttir. The topic of this project is to design a form fitting drug delivery patch, using 3D printing to comfortably adjust around the finger joint for hand osteoarthritis (HOA) patients. The patch will be multilayered, made up of 3D printed impermeable layer, a drug reservoir and a release liner.
Drug development of the phenazine 5,10-dioxide natural products iodinin and myxin into antileukemic candidates
Elvar Örn Viktorsson highlights research efforts to develop the phenazine 5,10-dioxide natural products iodinin and myxin into more promising drug leads for acute myeloid leukemia. Synthesis, biological evaluations and structure-activity relationship studies.
Unnur Arna Þorsteinsdóttir. The aim of this study was to optimize a UPLC-MS/MS plasma method for therapeutic drug monitoring in patients with APRT deficiency, utilizing the chemometric approach design of experiments (DoE).